Approval · Notice of Compliance 26248 · 2021
EDARBI: Notice of Compliance 26248
Issued July 13, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26248
- Date
- July 13, 2021
- Company
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Administrative: Change in Product Ownership Updates to the Product Labelling
Products in this notice
Medicinal ingredients
- AZILSARTAN MEDOXOMIL POTASSIUM 40 MG per TAB
- AZILSARTAN MEDOXOMIL POTASSIUM 80 MG per TAB